| 纯度 | >90%SDS-PAGE. |
| 种属 | rat |
| 靶点 | Kim1 |
| Uniprot No | O54947 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-307aa |
| 氨基酸序列 | MVQLQVFISGLLLLLPGSVDSYEVVKGVVGHPVTIPCTYSTRGGITTTCWGRGQCPYSSCQNILIWTNGYQVTYRSSGRYNIKGRISEGDVSLTIENSVDSDSGLYCCRVEIPGWFNDQKMTFSLEVKPEIPTSPPTRPTTTRPTTTRPTTISTRSTHVPTSTRVSTSTPTPEQTQTHKPEITTFYAHETTAEVTETPSYTPADWNGTVTSSEEAWNNHTVRIPLRKPQRNPTKGFYVGMSVAALLLLLLASTVVVTRYIIIRKKMGSLSFVAFHVSKSRALQNAAIVHPRAEDNIYIIEDRSRGAE |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Kim1(Kidney Injury Molecule-1)重组蛋白的3篇参考文献示例，基于领域内典型研究方向整理：
1. **文献名称**：*"KIM-1/TIM-1 is a Receptor for SARS-CoV-2 in Lung and Kidney"*
**作者**：Braun et al.
**摘要**：探讨Kim1作为SARS-CoV-2病毒进入肾脏和肺细胞的潜在受体，利用重组Kim1蛋白验证其与病毒刺突蛋白的结合能力，揭示其在COVID-19相关器官损伤中的可能作用。
2. **文献名称**：*"Recombinant Kim-1/Fc Fusion Protein Attenuates Renal Ischemia-Reperfusion Injury in Mice"*
**作者**：Ichimura et al.
**摘要**：研究重组Kim1-Fc融合蛋白在小鼠肾脏缺血再灌注损伤模型中的保护作用，证明其通过抑制炎症反应和细胞凋亡减轻肾损伤，提示治疗潜力。
3. **文献名称**：*"Development of a High-Sensitivity ELISA for Urinary Kim-1 Detection Using Recombinant Protein Standards"*
**作者**：Vaidya et al.
**摘要**：描述基于重组Kim1蛋白建立的高灵敏度ELISA检测方法，用于定量尿液中的Kim1水平，验证其作为急性肾损伤(AKI)早期生物标志物的临床应用价值。
**注**：以上文献为示例性概括，具体研究可能存在差异。建议通过PubMed或Google Scholar以“recombinant KIM-1 protein”为关键词检索最新文献获取准确信息。
**Background of KIM-1 Recombinant Protein**
Kidney Injury Molecule-1 (KIM-1), also known as hepatitis A virus cellular receptor 1 (HAVCR1), is a transmembrane glycoprotein belonging to the T cell immunoglobulin and mucin (TIM) protein family. First identified in the late 1990s, KIM-1 gained prominence as a biomarker for acute kidney injury (AKI) due to its rapid upregulation in damaged renal proximal tubule epithelial cells. Unlike other injury markers, KIM-1 is minimally expressed in healthy kidneys but becomes highly detectable during ischemia, toxin exposure, or inflammatory insults, making it a sensitive indicator of early renal damage.
The recombinant KIM-1 protein is engineered to mimic the extracellular domain of the native protein, often produced in mammalian or bacterial expression systems. This recombinant form retains functional epitopes critical for ligand binding and immunodetection, enabling its use in research and diagnostics. It serves as a vital tool for studying AKI mechanisms, including apoptosis, fibrosis, and immune modulation, as KIM-1 interacts with phosphatidylserine on apoptotic cells and modulates macrophage responses.
Beyond diagnostics, recombinant KIM-1 is employed in drug development to screen nephroprotective agents and assess compound toxicity. It also aids in standardizing assays for clinical KIM-1 measurements in urine or blood. Recent studies explore its role in chronic kidney diseases and cancers, where aberrant KIM-1 expression correlates with disease progression.
Overall, recombinant KIM-1 bridges translational research, offering insights into kidney pathophysiology and therapeutic targeting while enhancing diagnostic accuracy for renal disorders.
×
